Diagnostic News and Research

RSS

PharmaNet launches Initiator and PKS technology platforms to improve clinical study timelines

PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, is pleased to announce that it is launching two technology platforms – Initiator™ and PKS™ - that will provide dramatic improvements in clinical study timelines by accelerating data acquisition and the processing of final client reports in its Phase I clinics. By providing clients with real time data faster, sponsors can make informed decisions about their products earlier in the process.

15 Dec 2010

BSGI/MBI provides additional information when conventional imaging is indeterminate in diagnosing breast cancer

Dr. Barbara Ward and others of Weinstein Imaging determined that Breast-Specific Gamma Imaging/Molecular Breast Imaging (BSGI/MBI) provides additional information when conventional imaging is indeterminate and greater confidence is required to improve diagnostic accuracy. The data from the retrospective study demonstrated that BSGI contributed significantly to patient management by detecting cancer in 7 of the 73 patients (9%), and was presented last week at the San Antonio Breast Cancer Symposium.

15 Dec 2010

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

Cell Biosciences receives US Patent for NanoPro assay technology

Cell Biosciences, Inc. today announced the issuance of Patent No. 7,846,676 for "Methods and Devices for Analyte Detection" by the United States Patent and Trademark Office.

15 Dec 2010

New hypothesis emphasizes the value of anti-inflammatory approaches to prevent Alzheimer's disease

Karl Herrup thinks that the national research effort to understand Alzheimer-s disease has gone about as far as it can go with its current theories.

15 Dec 2010

Sniffer rats detect TB more accurately than traditional microscopic analysis

Trained giant African rats increased positive TB detection rates by 44 percent over microscopy, the most commonly-used technique for diagnosing TB, according to a new study released in the December issue of the American Journal of Tropical Medicine and Hygiene.

15 Dec 2010

Case study sheds light on pathological course of Alzheimer's disease

A case study from the Swedish medical university Karolinska Institutet sheds light on the pathological course of Alzheimer's disease. The brain of the first Alzheimer's patient to display amyloids demonstrable with a PET scanner has been studied, both during progression of the disease and after death.

15 Dec 2010

FP/TMEM127 gene germline mutations associated with adrenal gland tumors

Analysis has identified variations of a gene that are associated with a type of tumor that forms within the adrenal gland, according a study in the December 15 issue of JAMA. The age group in which these variations were found are frequently excluded from genetic screening models for this type of tumor.

15 Dec 2010

Life Technologies announces launch of Ion Personal Genome Machine sequencer

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has launched its Ion Personal Genome Machine (PGM™) sequencer, the first product to use semiconductor sequencing technology. The sequencer is shipping to select sites in North America, Europe and Asia Pacific.

14 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Lack of strong molecular 'glue' allows tumour cells to break away and spread

A remarkable discovery into how tumour cells invade normal tissue should lead to vital diagnostic tools and help develop strategies to stop the spread of cancer cells. A new study by scientists at the Montreal Neurological Institute and Hospital of McGill University reveals that the surface of aggressive tumour cells lack the strong molecular 'glue' responsible for binding normal cells together.

14 Dec 2010

FDA to review Lantheus' DEFINITY sNDA for use in stress echocardiography

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension for use in stress echocardiography.

14 Dec 2010

iMDsoft, Mindray enter new distribution agreement

iMDsoft®, a leader in hospital-wide clinical information systems, and Mindray, a leading global provider of medical devices, have today announced a new distribution agreement. Under the agreement, Mindray will sell only clinical information systems by iMDsoft, and will be the sole distributor of MetaVision® in China. Mindray will also distribute iMDsoft's MetaVision® Suite solutions in 10 countries in Europe, Africa, and Asia.

From Mindray 13 Dec 2010

Elsevier announces special Issue on Fetal Alcohol Spectrum Disorders

Elsevier Inc., the world's leading publisher of scientific, technical and medical information, announced today that Alcohol has published a special year-end double issue on Fetal Alcohol Spectrum Disorders (FASD). It fills an urgent need to bring the widest possible readership current perspectives on using new research methods to improve identification and diagnosis of offspring at risk for FASD and its associated brain damage and behavioral dysfunction.

13 Dec 2010

SunTech Medical, ADC launch ADView spot-check device

SunTech Medical and American Diagnostic Corporation announced today the launch of the ADView spot-check device. The ADView is a completely modular spot-check device capable of measuring blood pressure, temperature, and pulse oximetry in multiple clinical settings.

13 Dec 2010

NinePoint enters IP licensing agreement with Massachusetts General Hospital

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, NinePoint has certain exclusive rights in multiple fields to 188 patents and patent applications owned by MGH.

13 Dec 2010

Enzo Biochem first quarter total revenues increase 2% to $25.7 million

Enzo Biochem, Inc. today reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

13 Dec 2010

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

13 Dec 2010

Mayo clinic creates new computerized radiation tracking system

Mayo Clinic is initiating a new imaging exam tracking system that, among other things, enables a comprehensive view of a patient's radiation exposures over time.

13 Dec 2010

Research roundup: For-profit hospitals' readmission rate, containing self-referrals, children's dental health, revisiting McAllen

For-Profit Hospital Status And Rehospitalizations At Different Hospitals: An Analysis of Medicare Data - "Rehospitalization within the first 30 days of discharge affects 1 in 5 hospitalized Medicare fee-for-service patients and costs approximately $17.4 billion in payments annually ... the top 4 factors most related to the risk for rehospitalization at a different facility were initial admission to a for-profit index hospital … lower-volume index hospital (hospitals with <1000 annual discharges) … hospital with a major medical school affiliation … and being disabled."

10 Dec 2010